Deciding to administer CAR T-cell therapies is an institutional commitment that requires educating all clinicians who will be involved and partnerships with other organizations, said Stephen Schuster, MD, of the Perelman School of Medicine.
Deciding to administer CAR T-cell therapies is an institutional commitment that requires educating all clinicians who will be involved and partnerships with other organizations, said Stephen Schuster, MD, of the Perelman School of Medicine.
Transcript
What education efforts are needed for patients and clinicians when new treatments like CAR T therapies first emerge?
It’s an institutional commitment if one is going to do CAR T-cell therapy; it’s not just a single physician or physician’s office. It involves multiple people, there’s a chain of people that are involved from the blood bank or transfusion service that receives the cells and thaws the cells and administers the cells to the physicians and nurse practitioners and nurses that are caring for the patients during infusion and after infusion of the cells.
And those people need to be educated not only in the specific adverse events of special interest—cytokine release, neurotoxicity—but also in terms of handling the cells and making sure that the patient is in the proper environment for surveillance for subsequent syndromes, either as an outpatient or an inpatient, depending on the product used. Most leukemia patients, kids, will be admitted to the hospital.
So, what’s helpful is the sponsors of the 2 products that have a commercial label, that’s tisagenlecleucel or Kymriah, and the other one is axicabtagene ciloleucel, which is called Yescarta, they have REMS [Risk Evaluation and Mitigation Strategy] programs. So, these are programs that will educate people at all points in the chain on what to expect, what the roles are, what the proper responses are and actually have a test and things like that. And that’s the first step in getting educated.
Obviously, experience is important and the only way you can get that is by doing it. I think that people who are new to it, in addition to the REMS programs, should probably have a relationship with someone who is experienced, so if they run into problems they have somebody they can call and bounce problems off of.
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Read More
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More